Please wait a minute...
J Zhejiang Univ (Med Sci)  2020, Vol. 49 Issue (2): 147-157    DOI: 10.3785/j.issn.1008-9292.2020.02.02
    
Management of COVID-19: the Zhejiang experience
XU Kaijin1,2(),CAI Hongliu1(),SHEN Yihong1,NI Qin1,2,CHEN Yu1,HU Shaohua1,LI Jianping1,WANG Huafen1,YU Liang1,2,HUANG He1,QIU Yunqing1,WEI Guoqing1,FANG Qiang1,*(),ZHOU Jianying1,*(),SHENG Jifang1,2,*(),LIANG Tingbo1,*(),LI Lanjuan1,2,*()
1. The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
2. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China
Download: HTML( 226 )   PDF(1114KB)
Export: BibTeX | EndNote (RIS)      

Abstract  

The current epidemic situation of coronavirus disease 2019 (COVID-19) still remained severe. As the National Clinical Research Center for Infectious Diseases, the First Affiliated Hospital of Zhejiang University School of Medicine is the primary medical care center for COVID-19 in Zhejiang province. Based on the present expert consensus carried out by National Health Commission and National Administration of Traditional Chinese Medicine, our team summarized and established an effective treatment strategy centered on "Four-Anti and Two-Balance" for clinical practice. The "Four-Anti and Two-Balance" strategy included antivirus, anti-shock, anti-hyoxemia, anti-secondary infection, and maintaining of water, electrolyte and acid base balance and microecological balance. Meanwhile, integrated multidisciplinary personalized treatment was recommended to improve therapeutic effect. The importance of early viralogical detection, dynamic monitoring of inflammatory indexes and chest radiograph was emphasized in clinical decision-making. Sputum was observed with the highest positive rate of RT-PCR results. Viral nucleic acids could be detected in 10%patients' blood samples at acute period and 50%of patients had positive RT-PCR results in their feces. We also isolated alive viral strains from feces, indicating potential infectiousness of feces.Dynamic cytokine detection was necessary to timely identifying cytokine storms and application of artificial liver blood purification system. The "Four-Anti and Two-Balance" strategy effectively increased cure rate and reduced mortality. Early antiviral treatment could alleviate disease severity and prevent illness progression, and we found lopinavir/ritonavir combined with abidol showed antiviral effects in COVID-19. Shock and hypoxemia were usually caused by cytokine storms. The artificial liver blood purification system could rapidly remove inflammatory mediators and block cytokine storm.Moreover, it also favored the balance of fluid, electrolyte and acid-base and thus improved treatment efficacy in critical illness. For cases of severe illness, early and also short period of moderate glucocorticoid was supported. Patients with oxygenation index below 200 mmHg should be transferred to intensive medical center. Conservative oxygen therapy was preferred and noninvasive ventilation was not recommended. Patients with mechanical ventilation should be strictly supervised with cluster ventilator-associated pneumonia prevention strategies. Antimicrobial prophylaxis was not recommended except for patients with long course of disease, repeated fever and elevated procalcitonin (PCT), meanwhile secondary fungal infection should be concerned.Some patients with COVID-19 showed intestinal microbial dysbiosis with decreased probiotics such as Lactobacillus and Bifidobacterium, so nutritional and gastrointestinal function should be assessed for all patients.Nutritional support and application of prebiotics or probiotics were suggested to regulate the balance of intestinal microbiota and reduce the risk of secondary infection due to bacterial translocation. Anxiety and fear were common in patients with COVID-19. Therefore, we established dynamic assessment and warning for psychological crisis. We also integrated Chinese medicine in treatment to promote disease rehabilitation through classification methods of traditional Chinese medicine. We optimized nursing process for severe patients to promote their rehabilitation. It remained unclear about viral clearance pattern after the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Therefore, two weeks' quarantine for discharged patients was required and a regular following up was also needed.The Zhejiang experience and suggestions have been implemented in our center and achieved good results. However, since COVID-19 was a newly emerging disease, more work was warranted to improve strategies of prevention, diagnosis and treatment for COVID-19.



Key wordsCoronavirus disease 2019      Severe acute respiratory syndrome coronavirus 2      Novel coronavirus infection      Critical illness      Combined modality therapy      Multi-disciplinary team     
Received: 15 February 2020      Published: 21 February 2020
CLC:  R512.99  
Corresponding Authors: FANG Qiang,ZHOU Jianying,SHENG Jifang,LIANG Tingbo,LI Lanjuan     E-mail: zdyxyxkj@zju.edu.cn;1193001@zju.edu.cn;1183005@zju.edu.cn;zjyhz@zju.edu.cn;jifang_sheng@zju.edu.cn;liangtingbo@zju.edu.cn;ljli@zju.edu.cn
Cite this article:

XU Kaijin,CAI Hongliu,SHEN Yihong,NI Qin,CHEN Yu,HU Shaohua,LI Jianping,WANG Huafen,YU Liang,HUANG He,QIU Yunqing,WEI Guoqing,FANG Qiang,ZHOU Jianying,SHENG Jifang,LIANG Tingbo,LI Lanjuan. Management of COVID-19: the Zhejiang experience. J Zhejiang Univ (Med Sci), 2020, 49(2): 147-157.

URL:

http://www.zjujournals.com/med/10.3785/j.issn.1008-9292.2020.02.02     OR     http://www.zjujournals.com/med/Y2020/V49/I2/147


2019冠状病毒病(COVID-19)诊疗浙江经验

当前2019冠状病毒病(COVID-19)疫情仍处于胶着状态。浙江大学医学院附属第一医院是国家感染性疾病临床医学中心,浙江省COVID-19患者救治中心。疫情一线的专家集智攻关,以国家卫生健康委员会和国家中医药管理局发布的COVID-19诊治指南为依据,以抗病毒、抗休克、抗低氧血症、抗继发感染、维持水电解质和酸碱平衡、维持微生态平衡的“四抗二平衡”救治策略为核心,总结完善诊治方案,聚焦临床实践的一些具体问题,为COVID-19患者临床诊治提供借鉴。推荐以多学科协作诊治个性化治疗提高COVID-19患者救治质量。建议病原学检测、炎症指标监测和肺部影像学动态观察指导临床诊治。痰液的病毒核酸检测阳性率最高,约10%的急性期患者血液中检测到病毒核酸,50%的患者粪便中检测到病毒核酸,粪便中可分离出活病毒,须警惕粪便是否具有传染性;开展细胞因子等炎症指标监测有助于发现是否出现细胞因子风暴,判断是否需要人工肝血液净化治疗。通过以“四抗二平衡”为核心的综合治疗提高治愈率、降低病死率;早期抗病毒治疗能减少重症、危重症发生,前期使用阿比多尔联合洛匹那韦/利托那韦抗病毒显示出一定效果。休克和低氧血症多为细胞因子风暴所致,人工肝血液净化治疗能迅速清除炎症介质,阻断细胞因子风暴,对维持水电解质酸碱平衡也有很好的作用,可以提高危重型患者的疗效。重型病例疾病早期可适量、短程应用糖皮质激素。氧疗过程中,患者氧合指数小于200 mmHg时应及时转入重症医学科治疗;采用保守氧疗策略,不推荐常规进行无创通气;机械通气患者应严格执行集束化呼吸机相关性肺炎预防管理策略;氧合指数大于150 mmHg时,及早减、停镇静剂并撤机拔管。不推荐预防性使用抗菌药物,对于病程长,体温反复升高和血降钙素原水平升高的患者可酌情使用抗菌药物;要关注COVID-19患者继发真菌感染的诊治。COVID-19患者有肠道微生态紊乱,肠道乳酸杆菌、双歧杆菌等有益菌减少,推荐对所有患者进行营养和胃肠道功能评估,以营养支持和补充大剂量肠道微生态调节剂,纠正肠道微生态失衡,减少细菌移位和继发感染。COVID-19患者普遍存在焦虑和恐惧心理,应建立动态心理危机干预和处理。提倡中西医结合辨证施治;优化重型患者护理促进康复。严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染后病毒清除规律仍不明了,出院后仍须居家隔离2周,并定期随访。以上经验和建议在本中心实行,取得较好效果,但COVID-19是一种新的疾病,其诊治方案及策略仍有待进一步探索与完善。


关键词: 2019冠状病毒病,  严重急性呼吸综合征冠状病毒2,  新型冠状病毒感染,  危重病,  综合疗法,  多学科诊疗 
[1]   中国疾病预防控制中心.新型冠状病毒肺炎疫情分布[EB/OL].[2020-02-15]. http://2019ncov.chinacdc.cn/2019-nCoV/.
Chinese Center for Disease Control and Prevention.Distribution of novel coronavirus pneumonia[EB/OL].[2020-02-15]. http://2019ncov.chinacdc.cn/2019-nCoV/. (in Chinese)
[2]   WANG C , HORBY P W , HAYDEN F G et al. A novel coronavirus outbreak of global health concern[J]. Lancet, 2020,
doi: 10.1016/S0140-6736(20)30185-9
[3]   中国疾控中心在武汉华南海鲜市场检出大量新型冠状病毒[EB/OL].(2020-01-27)[2020-02-15].http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html.
China CDC has detected novel coronavirus in Southern China seafood market of Wuhan[EB/OL]. (2020-01-27)[2020-02-15]. http://www.chinacdc.cn/yw_9324/202001/t20200127_211469.html. (in Chinese)
[4]   中华人民共和国国家卫生健康委员会.国家卫生健康委关于新型冠状病毒肺炎暂命名事宜的通知[EB/OL].(2020-02-07)[2020-02-15].http://www.nhc.gov.cn/mohwsbwstjxxzx/s2908/202002/f15dda000f6a46b2a1ea1377cd80434d.shtml.
National Health Commission of the People's Republic of China. Notification of novel coronavirus pneumonia temporarily named by the National Health Commission of the People's Republic of China[EB/OL]. (2020-02-07)[2020-02-15]. http://www.nhc.gov.cn/mohwsbwstjxxzx/s2908/202002/f15dda000f6a46b2a1ea1377cd80434d.shtml. (in Chinese)
[5]   GORBALENYA A E. Severe acute respiratory syndrome-related coronavirus-the species and its viruses, a statement of the Coronavirus Study Group[J/OL]. BioRxiv, 2020. DOI: 10.1101/2020.02.07.937862.
[6]   WHO. Novel coronavirus (2019-nCoV) situation report-22[EB/OL]. (2020-02-11)[2020-02-11].https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/.
[7]   中华人民共和国国家卫生健康委员会疾病预防控制局.新型冠状病毒感染的肺炎纳入法定传染病管理[EB/OL].(2020-01-20)[2020-02-15]. http://www.nhc.gov.cn/jkj/s7915/202001/e4e2d5e6f01147e0a8df3f6701d49f33.shtml.
Bureau of Disease Control and Prevention, National Health Commission of the People's Republic of China. Novel coronavirus infection pneumonia is included in the management of notifiable infectious diseases[EB/OL].(2020-01-20)[2020-02-15]. http://www.nhc.gov.cn/jkj/s7915/202001/e4e2d5e6f01147e0a8df3f6701d49f33.shtml. (in Chinese)
[8]   中华人民共和国国家卫生健康委员会办公厅, 国家中医药管理局办公室.新型冠状病毒肺炎诊疗方案(试行第五版修正版)[A/OL].国卫办医函[2020] 117号. (2020-02-08)[2020-02-15].http://www.nhc.gov.cn/xcs/zhengcwj/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml.
General Office of National Health Commission of the People's Republic of China, Office of National Administration of Traditional Chinese Medicine. Diagnosis and treatment of novel coronavirus pneumonia (trial version 5 revised)[A/OL]. No.117[2020] of the General Office of the National Health Commission China. (2020-02-08)[2020-02-15]. http://www.nhc.gov.cn/xcs/zhengcwj/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml. (in Chinese)
[9]   CHEN Y , LIANG W , YANG S et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry:clinical analysis and characterisation of viral genome[J]. Lancet, 2013, 381 (9881): 1916- 1925
doi: 10.1016/S0140-6736(13)60903-4
[10]   GAO H N , LU H Z , CAO B et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection[J]. N Engl J Med, 2013, 368 (24): 2277- 2285
doi: 10.1056/NEJMoa1305584
[11]   LIU X , ZHANG Y , XU X et al. Evaluation of plasma exchange and continuous veno-venous hemofiltration for the treatment of severe avian influenza A (H7N9):a cohort study[J]. Ther Apher Dial, 2015, 19 (2): 178- 184
doi: 10.1111/1744-9987.12240
[12]   国家感染性疾病临床医学研究中心, 传染病诊治国家重点实验室 . 人工肝血液净化系统应用于重型、危重型新型冠状病毒肺炎治疗的专家共识[J]. 中华临床感染病杂志, 2020, 13 (1): 1- 3
National Clinical Research Center for Infectious Diseases , State Key Laboratory for Diagnosis and Treatment of Infectious Diseases . Expert consensus on the application of artificial liver blood purification system in the treatment of severe and critical COVID-19[J]. Chinese Journal of Clinical Infectious Diseases, 2020, 13 (1): 1- 3
doi: 10.3760/cma.j.issn.1674-2397.2020.01.001
[1] CHEN Zhimin,FU Junfen,SHU Qiang,WANG Wei,CHEN Yinghu,HUA Chunzhen,LI Fubang,LIN Ru,TANG Lanfang,WANG Tianlin,WANG Yingshuo,XU Weize,YANG Zihao,YE Sheng,YUAN Tianming,ZHANG Chenmei,ZHANG Yuanyuan. Diagnosis and treatment recommendation for pediatric COVID-19 (the second edition)[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 139-146.
[2] JIANG Saiping,LI Lu,RU Renping,ZHANG Chunhong,RAO Yuefeng,LIN Bin,WANG Rongrong,CHEN Na,WANG Xiaojuan,CAI Hongliu,SHENG Jifang,ZHOU Jianying,LU Xiaoyang,QIU Yunqing. Pharmaceutical care for severe and critically ill patients with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 158-169.
[3] LI Xin,DAI Tian,WANG Hong,SHI Junnian,YUAN Wei,LI Jing,CHEN Lijun,ZHANG Tianming,ZHANG Shanshan,KONG Yan,YUE Ning,SHI Hui,HE Yuping,HU Huifang,LIU Furong,YANG Caixia. Clinical analysis of suspected COVID-19 patients with anxiety and depression[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 203-208.
[4] LUO Song,YANG Lijuan,WANG Chun,LIU Chuanmiao,LI Dianming. Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 227-231.
[5] HONG Dongsheng,NI Jian,SHAN Wenya,LI Lu,HU Xi,YANG Hongyu,ZHAO Qingwei,ZHANG Xingguo. Establishment of a rapid identification of adverse drug reaction program in R language implementation based on monitoring data[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 253-259.
[6] ZHONG Qi,LI Zhi,SHEN Xiaoyong,XU Kaijin,SHEN Yihong,FANG Qiang,CHEN Feng,LIANG Tingbo. CT imaging features of patients with different clinical types of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 198-202.
[7] KANG Xianhui,ZHANG Rong,HE Huiliang,YAO Yongxing,ZHENG Yueying,WEN Xiaohong,ZHU Shengmei. Anesthesia management in cesarean section for patient with COVID-19: a case report[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 249-252.
[8] CHEN Xu,LI Yang,WANG Jinxi,CAI Hongliu,CAO Hongcui,SHENG Jifang. Pregnant women complicated with COVID-19: a clinical analysis of 3 cases[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 240-244.
[9] SHEN Lihua,HUANG Fei,CHEN Xiang,XIONG Zuan,YANG Xiaoyu,LI Hui,CHENG Feng,GUO Jian,GONG Guofu. Diagnostic efficacy of three test kits for SARS-CoV-2 nucleic acid detection[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 185-190.
[10] ZHAGN Sheng,LI Danping,CHEN Huazhong,ZHENG Dan,ZHOU Yiping,CHEN Baoguo,SHI Weiwu,LIN Ronghai. Dynamic inflammatory response in a critically ill COVID-19 patient treated with corticosteroids[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 220-226.
[11] LI Youjiang,HU Yingying,ZHANG Xiaodong,YU Yuanyuan,LI Bin,WU Jianguo,WU Yingping,XIA Xiaoping,XU Jian. Follow-up testing of viral nucleic acid in discharged patients with moderate type of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 270-274.
[12] YE Ziqi,HONG Yun,WU Xiuhua,HONG Dongsheng,ZHANG Yanfang,DONG Xihao,RAO Yuefeng,LU Xiaoyang. Management of a colon cancer patient complicated with COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 245-248.
[13] DING Shubo,YU Shi'an,CHEN Haijun,ZHANG Dehe,XU Yejin,ZHU Dan,CHENG Kun. Roles of multidisciplinary team in diagnosis and treatment of suspected cases of COVID-19[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 209-214.
[14] HE Guojun,HAN Yijiao,FANG Qiang,ZHOU Jianying,SHEN Jifang,LI Tong,PU Qibin,CHEN Aijun,QI Zhiyang,SUN Lijun,CAI Hongliu. Clinical experience of high-flow nasal cannula oxygen therapy in severe COVID-19 patients[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 232-239.
[15] FAN Tiantian, CHEN Yongcan, BAI Yu, MA Fengqi, WANG Hengcang, YANG Yiping, CHEN Jinxu, LIN Yuqi. Analysis of medication characteristics of traditional Chinese medicine in treating COVID-19 based on data mining[J]. J Zhejiang Univ (Med Sci), 2020, 49(2): 260-269.